Therapy News and Research

RSS

Detailed review findings of EMPOWER study to evaluate the Maestro System released

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced preliminary findings from its ongoing detailed review of its EMPOWER™ study, a randomized, double-blind, controlled pivotal study designed to evaluate the safety and efficacy of the Maestro® System in the treatment of obesity.

12 Nov 2009

Pioneering cardiologist and inventor in heart medicine passed away

William Ganz, M.D., an internationally-recognized leader and inventor in heart medicine, died Tuesday night of natural causes. He was 90.

12 Nov 2009

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Keryx Biopharmaceuticals, Inc. today announced that data from its Phase 1/2 clinical trial of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) has been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

12 Nov 2009

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor Ortho Biotech's Stelara, the first interleukin (IL)-12/23 inhibitor to enter the psoriasis drug market in the U.S., is expected to change the prescribing habits of dermatologists and substantially alter patient flow to currently marketed biologic agents, including Amgen's Enbrel and Abbott's Humira.

12 Nov 2009

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Trubion Pharmaceuticals, Inc. announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) Annual Meeting Dec. 5-8, 2009 in New Orleans, Louisiana.

12 Nov 2009

Gene therapy increases muscle size and strength with no adverse effects in monkeys: MDA

Four macaque monkeys that received injections of genes for a protein called follistatin into upper leg muscles experienced pronounced and durable increases in muscle size and strength and no adverse effects, the Muscular Dystrophy Association (MDA) announced today. The findings could have implications particularly for injured and aging people worldwide; and for tens of millions experiencing muscle loss associated with cancer, AIDs and muscle diseases.

12 Nov 2009

Resources to help understand stroke and carotid artery disease

The Society of Interventional Radiology offers numerous resources-including publications and the first-ever Catheter Lysis of Thromboembolic Stroke (CLOTS) course-for interventional radiologists, neuroradiologists, neurointerventionists, body interventionalists, and IR and INR fellows to aid in the understanding of stroke and carotid artery disease.

12 Nov 2009

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.

12 Nov 2009

First pediatric hospital to discharge child with mechanical heart assist device

Texas Children's Hospital is the nation's first pediatric hospital to discharge a child while on an intracorporeal ventricular assist device (VAD), a feat previously accomplished only at adult institutions. The patient, 16-year-old Francisco "Frank" De Santiago, who was implanted with a mechanical heart pump called the HeartMate II on May 19, 2009, was discharged on Oct. 29, 2009.

12 Nov 2009

Mental Health America and Prescription Audio team up to provide free sound therapy

Mental Health America today announced it is partnering with Prescription Audio, a Philadelphia-area based firm (Voorhees, N.J.), to make the company's scientifically based sound therapy available without charge as a download to veterans, active duty servicemen and women, their family members and health care providers.

12 Nov 2009

Investors are betting on upcoming medical study results of BioElectronics, says BioMedReports

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, reports that investors are betting that BioElectronics' (PINKSHEETS: BIEL) upcoming medical study results will be significant.

12 Nov 2009

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Allos Therapeutics, Inc. today announced that abstracts from studies of FOLOTYN™ (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009.

12 Nov 2009

Data supports the use of ExAblate as a safe, effective and durable treatment for uterine fibroids

InSightec Ltd. today announced that three new papers published in the November issue of Ultrasound in Obstetrics and Gynecology add to the growing body of data supporting the use of ExAblate(R) as a safe, effective and durable treatment for uterine fibroids.

12 Nov 2009

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

12 Nov 2009

IMS Health to launch comprehensive analytical tool for oncology market

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the upcoming launch of IMS Oncology QuantifierTM, a comprehensive, clinically rich analytical tool that enables the company’s clients to assess treatment opportunities and guide commercial decisions in the $48 billion global oncology market.

12 Nov 2009

Scientists find way to disarm "undruggable" protein; discovery lays foundation for new kind of cancer therapy

Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. Their discovery, published in the November 12 issue of Nature, lays the foundation for a new kind of therapy aimed directly at a critical human protein — one of a few thousand so-called transcription factors — that could someday be used to treat a variety of diseases, especially multiple types of cancer.

12 Nov 2009

Catheter-directed therapy: First-line treatment option for massive pulmonary embolism

Catheter-directed therapy or catheter-directed thrombolysis-an interventional radiology treatment that uses targeted image-guided drug delivery with specially designed catheters to dissolve dangerous blood clots in the lungs-saves lives and should be considered a first-line treatment option for massive pulmonary embolism, note researchers in the November Journal of Vascular and Interventional Radiology.

12 Nov 2009

CVS Caremark's medication adherence program for people with diabetes has positive impact

CVS Caremark said the company's comprehensive adherence program for people with diabetes positively impacts medication adherence for both new and continuing patients. A review of data tracking the program found that 75.6 percent of patients continuing on a diabetes therapy who participated in the adherence program maintained optimal adherence to their prescribed therapy vs. 61.2 percent in the control group.

12 Nov 2009

Gene delivery strategy to help improve muscle mass in patients with degenerative muscle disorders

Severe weakness of the quadriceps is a defining feature of several neuromuscular disorders. Researchers at Nationwide Children's Hospital have shown that a gene delivery strategy that produces follistatin - a naturally occurring protein that inhibits myostatin, a growth factor expressed specifically in skeletal muscle - directly to the quadriceps of non-human primates results in long-term gene expression with muscle enhancing effects, including larger muscles with greater strength.

12 Nov 2009

Experts recommend nicotine replacement products and counseling to quit smoking

Whether you smoke three cigarettes or three packs of cigarettes a day, kicking the habit is difficult. Various nicotine replacement products are on the market to make quitting easier. But which product is right for you? Experts from The University of Texas M. D. Anderson Cancer Center are here to help.

12 Nov 2009

Therapy News and Research

Detailed review findings of EMPOWER study to evaluate the Maestro System released

Pioneering cardiologist and inventor in heart medicine passed away

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Gene therapy increases muscle size and strength with no adverse effects in monkeys: MDA

Resources to help understand stroke and carotid artery disease

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

First pediatric hospital to discharge child with mechanical heart assist device

Mental Health America and Prescription Audio team up to provide free sound therapy

Investors are betting on upcoming medical study results of BioElectronics, says BioMedReports

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Data supports the use of ExAblate as a safe, effective and durable treatment for uterine fibroids

Nuvo Research announces new licensing agreement for Oxoferin

IMS Health to launch comprehensive analytical tool for oncology market

Scientists find way to disarm "undruggable" protein; discovery lays foundation for new kind of cancer therapy

Catheter-directed therapy: First-line treatment option for massive pulmonary embolism

CVS Caremark's medication adherence program for people with diabetes has positive impact

Gene delivery strategy to help improve muscle mass in patients with degenerative muscle disorders

Experts recommend nicotine replacement products and counseling to quit smoking

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News